Parker Kerrigan Brittany C, Hossain Anwar, Yamashita Shinji, Lang Frederick F
Prog Neurol Surg. 2018;32:124-151. doi: 10.1159/000469686. Epub 2018 Jul 10.
Stem cells (SC) are the seeds of tissue repair and regeneration that have been extensively investigated as tumor-tropic vectors for gene delivery to solid cancers. SC have an inherent glioma tropism that supports their use as reliable vehicles to deliver therapeutic gene products to brain neoplasms. Several types of adult SC (ASC) have been used to carry antiglioma agents, and neural SC (NSC) and mesenchymal SC (MSC) are the most studied. The therapeutic cargoes that have been tested include secreted proteins, converting enzyme/prodrug suicide combinations, oncolytic viruses, antibodies, and nanoparticles. Some of these preclinical studies have advanced to phase I clinical trials. Use of SC as carriers to deliver various antitumor agents could become a valuable therapeutic option for glioma patients in the future.
干细胞（SC）是组织修复和再生的种子，已被广泛研究作为向实体癌进行基因递送的肿瘤靶向载体。SC具有内在的胶质瘤嗜性，这支持它们作为可靠的载体将治疗性基因产物递送至脑肿瘤。几种类型的成体干细胞（ASC）已被用于携带抗胶质瘤药物，其中神经干细胞（NSC）和间充质干细胞（MSC）是研究最多的。已测试的治疗性载荷包括分泌蛋白、转化酶/前药自杀组合、溶瘤病毒、抗体和纳米颗粒。其中一些临床前研究已进入I期临床试验。使用SC作为载体递送各种抗肿瘤药物可能在未来成为胶质瘤患者的一种有价值的治疗选择。
